Federal workers are suing the Trump administration to force taxpayers back onto the hook for hormone treatments and sex-change surgeries — another bid to override elected policy through the courts.
The Human Rights Campaign Foundation filed suit Monday against the Office of Personnel Management, arguing that stripping so-called "gender-affirming care" from federal employee health plans violates anti-discrimination law. The policy took effect in January and affects an estimated 39,400 enrollees covered under federal insurance plans, according to the Williams Institute at UCLA School of Law. Federal insurance covers roughly 8.3 million people total — employees, retirees, and their families.
OPM issued the prohibition quietly last summer through a carrier letter, forbidding insurance companies that contract with the federal employee benefit programs from covering gender-affirming care regardless of age. The ban expanded on an earlier prohibition limited to minors. A temporary exception for those "mid-treatment" was eliminated effective 2027 via a subsequent letter in March. Mental health counseling, including faith-based counseling, remains covered.
The lawsuit's anonymous plaintiffs include a State Department employee identified as Gregory Goe, who has been on hormone replacement therapy for eight years. According to the complaint, Goe's Blue Cross Blue Shield plan stopped covering the treatment, and his surgeon will not schedule surgery without insurance coverage — leaving him facing over $100,000 in out-of-pocket costs. A U.S. Postal Service employee identified as Patrick Poe lost coverage for his transgender daughter's care, forcing the family to "deplete their savings," the complaint states. Another plaintiff who had surgery previously covered now requires post-surgical care that is no longer covered.
HRCF president Kelley Robinson called the policy an effort to "weaponize" health care coverage to discriminate against transgender workers. The complaint compares denying gender-affirming care to denying insulin treatment for diabetics. Cynthia Cheng-Wun Weaver, HRCF's senior director of litigation, said the financial burdens amount to prohibition for some individuals even though the ban targets insurance coverage, not the care itself.
HuffPost framed the policy as a "categorical denial of treatment" and emphasized the personal cost to affected workers. The Guardian noted that major medical organizations support gender-affirming care as "medically necessary" and highlighted the confusion around the mid-treatment exception. Neither outlet dwelled on the underlying question: whether taxpayers should be compelled to subsidize irreversible medical interventions through the benefits they fund.
The lawsuit, filed with the D.C. law firm Correia & Puth, seeks an injunction reversing the policy and restoring coverage, plus damages. It argues the prohibition violates Title VII protections against sex discrimination.
The question now is whether a judge will substitute his judgment for the executive branch's authority to set the terms of employment benefits that American taxpayers finance — or whether the people who pay the bills get a say through their elected government.
